Idelalisib (CAL-101, GS-1101)

目录号:S2226

Idelalisib (CAL-101, GS-1101) Chemical Structure

Molecular Weight(MW): 415.42

Idelalisib (CAL-101, GS-1101) 是选择性p110δ抑制剂,在无细胞试验中IC50为 2.5 nM;对 p110δ 表现出的选择性是对 p110α/β/γ 的 40 到 300 倍,对p110δ的选择性是对 C2β,hVPS34,DNA-PK 和 mTOR的400到4000倍。

规格 价格 库存 购买数量  
RMB 1279.19 现货
RMB 972.85 现货
RMB 3867.24 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献38篇:

客户使用该产品的6个实验数据:

  • Invasive migration of RA FLS was analyzed through growth factor–reduced Matrigel-coated transwell inserts in the presence or absence of 1 µM INK007, 5 µM CAL-101, or 0.3 µM IPI-145, or 0.3 µM GDC-0941 inhibitors or DMSO. Cells were allowed to invade through Matrigel toward PDGF-BB (25 ng/ml) containing media for 24 h and were fixed and stained with Hemacolor staining kit.

    J Immunol, 2014, 192(5): 2063-70 . Idelalisib (CAL-101, GS-1101) purchased from Selleck.

    Ppp2r1afl/fl BCR-ABL1 B-ALL cells transduced with 4-OHT-inducible Cre-ERT2 (Cre) or ERT2-vector (EV) were treated with 4-OHT for 3 days and cell lysates were studied by phospho-protein array analysis. Ppp2r1afl/fl BCR-ABL1 ALL cells were transduced with 4-OHT-inducible Cre or EV control and incubated in the presence of the small molecule signaling inhibitor idelalisib (32 μmol/L; C). Percentages of GFP+ cells were measured by flow cytometry at the times indicated following 4-OHT-treatment. Data are shown as mean ± standard deviation (SD) and representative of at least three independent experiments.

    Cell, 2018, 173(2):470-484. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

  • Rolling and sticking fractions of calcein-labeled CLL cells from a patient with bulky disease are shown before treatment, and at 3 or 7 weeks under idelalisib treatment. Mean ± SD, venular order III (n = 3), order IV (n = 4), order V (n = 3-4). Unpaired t test; *P < .05, **P < .01.

    Blood, 2016, 127(25):3192-201. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

    293T cells were transfected with HA-tagged Fbxo45. At 48 h after transfection, cells were treated with AKT inhibitor (CAL-101; 10 uM, 4 h), cell extracts from the cytoplasm or nuclei were subjected to IP with anti-HA resin followed by western blot analysis with indicated antibodies.

    Cell Death Differ 2014 21(10), 1535-45. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

  • Isoform-selective PI3K inhibitors blocked PI3K signaling in corresponding Rh30-Myr-p110 cells. Rh30-Myr-p110s cells were cultured in serum-free medium for 12 h, and then exposed to CAL-101 at indicated concentrations for additional 1 h. The cells were collected to detect the level of phosphorylated and total Akt. β-Actin was served as loading control.

    Acta Pharmacol Sin 2013 34(9),1201-7. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

    After starved in serum-free medium for 24 h,A549 cells incubated with the indicated concentrations of CAL-101 for 3 h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 Idelalisib (CAL-101, GS-1101) 是选择性p110δ抑制剂,在无细胞试验中IC50为 2.5 nM;对 p110δ 表现出的选择性是对 p110α/β/γ 的 40 到 300 倍,对p110δ的选择性是对 C2β,hVPS34,DNA-PK 和 mTOR的400到4000倍。
特性 Calistoga 暗示 CAL-101治疗血液恶性肿瘤可能有更广泛的应用价值。
靶点
p110δ [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
2.5 nM 89 nM
体外研究

CAL-101 对p110α, p110β,和p110γ作用效果不大。CAL-101作用于原代嗜碱细胞特定阻断FcϵR1 p110δ调节的 CD63表达,EC50 为8 nM。与急性髓性白血病(AML) 和骨髓增生性肿瘤(MPN) 细胞相比,CAL-101 作用于B-cell急性淋巴细胞白血病(B-ALL)和慢性淋巴细胞白血病(CLL) 细胞时显示更强的活性。CAL-101 作用于SU-DHL-5, KARPAS-422 和CCRF-SB细胞,降低pAktS473, pAktT308, 和下游靶点S6, EC50为0.1到1.0 μM。 [1] CAL-101 作用于CLL细胞,诱导选择性细胞毒性,不是通过突变状态或间期细胞遗传学,主要通过caspase依赖机制。与正常B细胞相比,CAL-101作用于CLL 细胞优先产生细胞毒性,和LY294002相比,作用于其他造血细胞不会产生毒性。CAL-101 作用于T 细胞和天然杀伤细胞 缺乏直接的细胞毒性潜能。CAL-101抑制炎症细胞因子的产生,比如 IL-6, IL-10, TNF-α,和IFN-γ,且激活诱导的细胞因子,如CD40L。CAL-101 也抗CD40L调节的CLL细胞存活。[2] CAL-101 作用于L1236和L591细胞, 诱导细胞在G1期积累,在S期下降,说明 CAL-101可以作为治疗霍杰金淋巴瘤(HL)的一种新策略。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MEC1 MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfGXGZFVVOR M4HSWmlEPTB;MkCuOEDPxE1? NX7iU|hrOjV7OUmzOVI>
CLL PBMCs MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTEUXNQ M2PEbWlEPTB;Mj65JI5O MkCwNlU6OTd{Nke=
U266 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGO0SYU1OCEQvF2= NGjvc|Q1QCCq MYC3PU42LSCrbnjpZol1cW:wIILheIU> M3roOVI2OzN7M{Oy
K562 M2jZb2Z2dmO2aX;uJGF{e2G7 NEH2O4YyKM7:TR?= M3\Sc|MhcA>? MX3Jcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25? M4G5fFI2ODF2N{e1
K562 MV7GeY5kfGmxbjDBd5NigQ>? NEfDSowyKM7:TR?= NX\tPXBMOyCq MU\Jcohq[mm2aX;uJI9nKFB5MGO2T{BxcG:|cHjvdplt[XSrb36= M4HYS|I2ODF2N{e1
K562 NULaOW5PTnWwY4Tpc44hSXO|YYm= NVfWc5ZIOSEQvF2= NHXSVo0{KGh? MWrJcohq[mm2aX;uJI9nKEeVS{OgdIhwe3Cqb4L5cIF1cW:w NHzPU40zPTBzNEe3OS=>
K562 NGrkPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYOxJO69VQ>? NWHLZ4VZPzJiaB?= MkPPTY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;u NVXrW485OjVyMUS3O|U>
Primary AML cell MWLGeY5kfGmxbjDBd5NigQ>? MoPCNUDPxE1? MX6zJIg> NV\pb41UUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;u NWfIdopVOjVyMUS3O|U>
Primary AML cell NHP6XJZHfW6ldHnvckBCe3OjeR?= NGfqfXcyKM7:TR?= M{LZTFMhcA>? NUT1VWdmUW6qaXLpeIlwdiCxZjDQO|BUPkticHjvd5Bpd3K7bHH0bY9v M1Ly[lI2ODF2N{e1
Primary AML cell MVvGeY5kfGmxbjDBd5NigQ>? MoewNUDPxE1? MWGzJIg> NI[zdllKdmirYnn0bY9vKG:oIFfTT|MheGixc4Doc5J6dGG2aX;u M{POUVI2ODF2N{e1
Primary AML cell NWTTWGJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Xyc|Eh|ryP NVLncmxjOyCq NVO4V5c6W3WycILld5Nqd25ib3[gdnJPSSC|eX70bIV{cXN? NX;Lc|RSOjVyMUS3O|U>
Microglia NITDUJFHfW6ldHnvckBCe3OjeR?= NWP6R4lJPSEQvF2= M1vGdlExKGh? NV23VVdYTE2VTx?= MUfE[YNz\WG|ZTDv[kBVVk[jIIPlZ5JmfGmxbjDmdo9uKEySUz3zeIlufWyjdHXkJEBxOTFyzsTEPVExSS:GOUGwRUBucWO{b3fsbYE> NVfRTYFNOjR4MkW2PFQ>
Primary CLL cell MVzGeY5kfGmxbjDBd5NigQ>? M3;SdVEh|ryP MnjpNVUhdWmw MnjoSG1UVw>? NWHsfHpDSmyxY3vzJGJEWi2rbnT1Z4VlKEyFUEGgd4VzcW6nLUWgZYN1cX[jdHnvci=> MoPuNlQxODl{M{O=
JEKO-1 MYPGeY5kfGmxbjDBd5NigQ>? NV7HbJJzOSEQvF2= NVO0T3BNPzJiaB?= MX3Jcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25iaX6gTYdONXO2aX31cIF1\WRiSlXLU{0y M1uyU|I{OzRzNUSx
Granta-519 NVjZTWZWTnWwY4Tpc44hSXO|YYm= NVvoSolZOSEQvF2= MlPyNkBp MmrITY5pcWKrdHnvckBw\iCDa4SoeFMxQClicHjvd5Bpd3K7bHH0bY9v NYTsbXhbOjN|NEG1OFE>
Granta-519 Mn;OSpVv[3Srb36gRZN{[Xl? MXqxJO69VQ>? MlTKNkBp MmfzTY5pcWKrdHnvckBw\iCDa4Sod|Q4OylicHjvd5Bpd3K7bHH0bY9v MYqyN|M1OTV2MR?=
JEKO-1 M3HGZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELhfY8yOCEQvF2= NF;s[2c4OiCq M2fre2lvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckB{dGmpaITsfS=> NIDoc5UzOzN2MUW0NS=>
JEKO-1 NYnie5FmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYO1JO69VQ>? NGnQXnQ4OiCq MWXkc4V{KG6xdDDpcoR2[2ViY3XscEBkgWOuZTDhdpJme3Rib4KgZZBweHSxc3nz NW\aVnF5OjN4N{[yNlA>
MAVER-1 NHrjO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrwVWY2KM7:TR?= NV;sRWRWPzJiaB?= MUHkc4V{KG6xdDDpcoR2[2ViY3XscEBkgWOuZTDhdpJme3Rib4KgZZBweHSxc3nz Mmm5NlM3PzZ{MkC=
MINO NFfPVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX61JO69VQ>? NVe4eFBnPzJiaB?= MnPY[I9meyCwb4SgbY5lfWOnIHPlcIwh[3mlbHWgZZJz\XO2IH;yJIFxd3C2b4Ppdy=> NEHMN24zOzZ5NkKyNC=>
SP53 NHHCd|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHSNE4yKM7:TR?= NEjmNZY4OiCq MX7kc4V{KG6xdDDpcoR2[2ViY3XscEBkgWOuZTDhdpJme3Rib4KgZZBweHSxc3nz NV7DcWttOjN4N{[yNlA>
HH MorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jrTVExKM7:TR?= MUi3NkBp MVrEUXNQ NW[4RnpTUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDzcIlocHSueR?= NVnCO5h{OjJ6MEG5OVk>
Myla M3:wV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfGXmJ4OTBizszN NHnme4E4OiCq MkDKSG1UVw>? NH7ZcINld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nz M4HOb|IzQDBzOUW5
SR786 M2fiUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTFT2QyOCEQvF2= NGDibZM4OiCq MVPEUXNQ MmLo[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?= NUL3SZBNOjJ6MEG5OVk>
HuT78 NHuzWVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7RSIEyOCEQvF2= M1nXTVczKGh? MXnEUXNQ NVTudWVw\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=> NF65PJczOjhyMUm1PS=>
MJ MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDSTGplOTBizszN Mnn6O|IhcA>? MWLEUXNQ M1S2O4Rw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYO= MX:yNlgxOTl3OR?=
DERL7 NFfYSHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvNNVAh|ryP NIr6OVQ4OiCq Mn;2SG1UVw>? NYnUUo8y\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=> MkGwNlI5ODF7NUm=
L1236 NIL4cnBHfW6ldHnvckBCe3OjeR?= NEGybZUyOCEQvF2= M2rPR|IhcA>? MljETY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:w M4rSbFIzOjFyOEe3
L428 MkXwSpVv[3Srb36gRZN{[Xl? MWWxNEDPxE1? M{XXZVIhcA>? M{jSeGlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbh?= MmHZNlIzOTB6N{e=
L591 MnfDSpVv[3Srb36gRZN{[Xl? M4\oNlExKM7:TR?= NFLXOZczKGh? M3r0b2lvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbh?= NF\ZU24zOjJzMEi3Oy=>
KMH-2 NFW3RpRHfW6ldHnvckBCe3OjeR?= Mn[0NVAh|ryP NWr6fWxvOiCq MUXJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25? NFfPT40zOjJzMEi3Oy=>
L1236 MlvmSpVv[3Srb36gRZN{[Xl? M3KyNlUh|ryP M33u[FI1KGh? NYPISoFZSmyxY3vzJJNm[3KndHnvckBw\iC2aHWgR2NNPQ>? MonNNlIzOTB6N{e=
L591 NWSyT405TnWwY4Tpc44hSXO|YYm= MmDWOUDPxE1? NYe1S3ZROjRiaB?= M1HKZ2Jtd2OtczDz[YNz\XSrb36gc4YhfGinIFPDUFU> NWXDfoI5OjJ{MUC4O|c>
L1236 MkDRRZBweHSxc3nzJGF{e2G7 M1LGbVUh|ryP NETrfoszPCCq M4jUSWlv\HWldHnvckBw\iCjcH;weI9{cXN? Ml[zNlIzOTB6N{e=
L591 NV3PTVJoSXCxcITvd4l{KEG|c3H5 MkXxOUDPxE1? MUKyOEBp MX7JcoR2[3Srb36gc4Yh[XCxcITvd4l{ MW[yNlIyODh5Nx?=
U-87MG MoLVSpVv[3Srb36gRZN{[Xl? MUCxNFAhdk1? M3PPc|I1KGh? MknaSG1UVw>? MmHBTY5pcWKrdHnvckBw\iBiY3XscEBucWe{YYTpc44> MoLZNlIxPzl4MEm=
SW1783 NUDwOJd6TnWwY4Tpc44hSXO|YYm= MXmxNFAhdk1? MVKyOEBp MoLWSG1UVw>? NWL1UGdXUW6qaXLpeIlwdiCxZjCgZ4VtdCCvaXfyZZRqd25? MYWyNlA4QTZyOR?=
U-87MG MUDGeY5kfGmxbjDBd5NigQ>? MXi1JO69VQ>? MnO2NlQhcA>? MkP1SG1UVw>? NHfobVhKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36gd5Vje3SjboTpZYxtgQ>? MUSyNlA4QTZyOR?=
SW1783 M33reGZ2dmO2aX;uJGF{e2G7 NHH0d2c2KM7:TR?= MX2yOEBp NHnTOW1FVVOR NFzWNG5KdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36gd5Vje3SjboTpZYxtgQ>? M{jxUlIzODd7NkC5
U-373MG NYX3V5hYTnWwY4Tpc44hSXO|YYm= M4flPVUh|ryP MnnkNlQhcA>? M2noZWROW09? M4H6NWlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbjDzeYJ{fGGwdHnhcIx6 M1nIN|IzODd7NkC5
SK-MG3 MlPTSpVv[3Srb36gRZN{[Xl? NVHPT2NPPSEQvF2= NVL6R4l[OjRiaB?= NEf1e21FVVOR NVvGb3htUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;uJJN2[nO2YX70bYFtdHl? M1zLVVIzODd7NkC5
SU-DHL-5 Ml7ESpVv[3Srb36gRZN{[Xl? NEC1XXgyKM7:TR?= NUPZfHZ6OjRiaB?= NET5VG5FVVOR NX6zUYRbUW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?= MlfRNlA6PTl4ME[=
WSU-NHL NIjyUXNHfW6ldHnvckBCe3OjeR?= NETjXGQyKM7:TR?= NIPPUoMzPCCq MV;EUXNQ MmHkTY5lfWO2aX;uJI9nKGGyb4D0c5Nqew>? NGDQWm4zODl3OU[wOi=>
CCRF-SB NF30cY1HfW6ldHnvckBCe3OjeR?= M3qyclEh|ryP MUGyOEBp MlToSG1UVw>? MX\JcoR2[3Srb36gc4Yh[XCxcITvd4l{ NILNPWozODl3OU[wOi=>
INA-6 NWrRfnZyTnWwY4Tpc44hSXO|YYm= MnTGOUDPxE1? M1zo[VYhcA>? NVj2fZZTUW6qaXLpeIlwdiCxZjDQTVNMN0GtdDDhcoQhTVKNIIDheIh4[Xl? NVuzZ4o2OjB3MEWxOVg>
LB NInkOo9HfW6ldHnvckBCe3OjeR?= NGHqUJM2KM7:TR?= NEi4UG43KGh? MnTVTY5pcWKrdHnvckBw\iCSSUTLM2FsfCCjbnSgSXJMKHCjdHj3ZZk> NX;RW4ZZOjB3MEWxOVg>

... Click to View More Cell Line Experimental Data

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[2]
+ 展开

PI3K实验:

用全CLL和正常B细胞溶解物进行PI3K实验。 进行PI3K ELISA 实验。全细胞抽提物加到PI(4,5)P2 底物和反应 buffer(包含 ATP)的混合物中,在室温下温育。加入 PI(3,4,5)P3 探测器和 EDTA混合,反应终止,在室温下温育1小时。混合物转移到PI3K ELISA板上,再温育1小时。 冲洗反应板,然后和第二探测器再温育30分钟。再次冲洗反应板, 加入3,3′,5,5′-四甲基联苯胺溶液 ,反应5分钟,加入H2SO4 终止反应。在450纳米处读数。
细胞实验:[2]
+ 展开
  • Cell lines: CLL B 细胞或健康志愿者的T细胞或NK细胞
  • Concentrations: 0.01-100 μM
  • Incubation Time: 48小时
  • Method: 进行MTT实验测定细胞毒性。1×105个细胞和CAL-101一起温育。加入MTT试剂, 再次温育20小时,然后用溶于PBS的硫酸鱼精蛋白冲洗。加入DMSO, 用分光光度计在540纳米处测定吸光度。使用膜联蛋白/PI液式细胞计检查在不同时间点测定细胞存活力,分析数据。每个样本至少计数104个细胞。以全部阳性细胞与未处理细胞之比百分数的形式来表示实验结果。加入100 μM Z-VAD检测caspase-依赖的细胞凋亡。加入 1 μg/mL CD40L, 800 U/mL IL-4, 50 ng/mL BAFF, 20 ng/mL TNF-α测定存活信号, 或者共培养在纤连蛋白或 HS-5 细胞系基质包被的板上。 基质共培养 在75cm2培养瓶 (80%-100% 融合率) 培养24 小时,然后加入CLL细胞。
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 83 mg/mL warmed (199.79 mM)
Ethanol 23 mg/mL (55.36 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
30% PEG 400 (dissolve first)+0.5% Tween 80+5% Propylene glycol
30mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 415.42
化学式

C22H18FN7O

CAS号 870281-82-6
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03349346 Withdrawn Diffuse Large B-Cell Lymphoma|Mediastinal B-cell Lymphoma Gilead Sciences June 2019 Phase 1
NCT03349346 Withdrawn Diffuse Large B-Cell Lymphoma|Mediastinal B-cell Lymphoma Gilead Sciences June 2019 Phase 1
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03639324 Not yet recruiting Chronic Lymphocytic Leukemia|CLL|Relapsed CLL|Refractory Chronic Lymphocytic Leukemia|Relapsed Chronic Lymphocytic Leukemia Virginia Commonwealth University March 30 2019 Phase 1
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03639324 Not yet recruiting Chronic Lymphocytic Leukemia|CLL|Relapsed CLL|Refractory Chronic Lymphocytic Leukemia|Relapsed Chronic Lymphocytic Leukemia Virginia Commonwealth University March 30 2019 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What is the recommended dose of CAL-101 and the route of administration for mouse studies?

  • 回答:

    According to the following paper, S2226 can be used by I.V. administration at the concentration of 40 mg/kg. https://www.ncbi.nlm.nih.gov/pubmed/24625684

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买Idelalisib (CAL-101, GS-1101) | Idelalisib (CAL-101, GS-1101)供应商 | 采购Idelalisib (CAL-101, GS-1101) | Idelalisib (CAL-101, GS-1101)价格 | Idelalisib (CAL-101, GS-1101)生产 | 订购Idelalisib (CAL-101, GS-1101) | Idelalisib (CAL-101, GS-1101)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID